Fairvalue-Calculator Fairvalue-Calculator
EN DE

Evome Medical Technologies Inc (EVMT) Fair Value & Analysis

Healthcare · CA · Market cap C$414K

PriceC$0.0050
Fair ValueC$0.0068
Upside+35.0%
Quality85/100
Evidence: Low Range C$0.0063 – C$0.0083

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Evome Medical Technologies Inc (EVMT) currently trades at C$0.0050, while our model-based Fair Value estimate is C$0.0068 — implying the stock looks roughly 35.0% undervalued today. We read business quality at 85/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Evome Medical Technologies Inc. designs, develops, produces, and sells medical devices in the United States. The company was formerly known as Salona Global Medical Device Corporation and changed its name to Evome Medical Technologies Inc. in January 2024. The company is based in Shirley, New York.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -95% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -11% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Evome Medical Technologies Inc (EVMT) undervalued?
As of Jun 26, 2026, our model estimates a fair value of C$0.0068 versus a price of C$0.0050 — about +35% (undervalued). Model-based estimate, not financial advice.
What is the fair value of EVMT?
Our 21-model fair value for Evome Medical Technologies Inc is C$0.0068 (as of Jun 26, 2026), built from audited fundamentals. The current price is C$0.0050.
What is the quality score of EVMT?
Evome Medical Technologies Inc has a Quality Score of 85/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.